Investigating the Accuracy of the openFDA API using the FDA Adverse Event Reporting System (FAERS)

被引:0
|
作者
Shin, Jennifer [1 ]
机构
[1] 8 Path Solut LLC, New York, NY 10024 USA
来源
2014 IEEE INTERNATIONAL CONFERENCE ON BIG DATA (BIG DATA) | 2014年
关键词
openFDA; FDA; adverse events; FDA Adverse Events Reporting System; FAERS; SURVEILLANCE;
D O I
暂无
中图分类号
TP [自动化技术、计算机技术];
学科分类号
0812 ;
摘要
The US Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) is a database that contains information on adverse event and medication error reports submitted to the FDA. Each quarter the FDA releases the data to the public, but accessing the data requires researchers to download, import, and consolidate data for every quarter starting from 2004. In an effort to provide easier access to this, the FDA launched the openFDA initiative in June 2014, which gives the public API access to information about adverse events reports. Although the API enables easier access to the FAERS data, the quality of the API design and the features of the data set will determine the reliability of the information retrieved. Thus, errors in the API can result in inaccurate and unreliable data analysis. Furthermore, the number of adverse events reports retrieved by the API for a particular drug can differ from the FAERS data files due to the openFDA harmonization process and the existence of multiple entries and variations for any given drug name in the FAERS data files. Since there are no universal rule that can be used to identify errors or potential issues, we propose evaluating the openFDA API by searching for a particular drug (brand name), Yaz, and the generic name, Drospirenone Ethinyl Estradiol, and comparing the results against the FAERS data files. Our results show that in the case of Yaz, the openFDA API and the drug harmonization process is inaccurate and inconsistent.
引用
收藏
页数:6
相关论文
共 50 条
  • [31] Cardiovascular toxicity profile of doxorubicin: data mining of the FDA adverse event reporting system (FAERS)
    Kattan, L.
    Cerbito, E.
    Dhulkifle, H.
    Korashy, H.
    Maayah, Z.
    CARDIOVASCULAR RESEARCH, 2024, 120
  • [32] Compartment syndrome associations with drugs: a pharmacovigilance study of the FDA adverse event reporting system (FAERS)
    Kong, Wenqiang
    Shu, Yunfeng
    Tang, Juan
    Wan, Jie
    Yang, Xueting
    EXPERT OPINION ON DRUG SAFETY, 2024,
  • [33] A REALWORLD PHARMACOVIGILANCE STUDY OF FDA ADVERSE EVENT REPORTING SYSTEM (FAERS) EVENTS FOR EMPAGLIFLOZIN AND DAPAGLIFLOZIN
    Milutinovic, Stefan
    Petrovic, Marija
    Jancic, Predrag
    Trajkovic, Hristina
    Alarcon, Ricardo Orlando Escarcega
    Chazal, Richard A.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2024, 83 (13) : 319 - 319
  • [34] Evaluation of Ticagrelor Bleeding Adverse Event Reports Compared to Clopidogrel in the FDA Adverse Events Reporting System (FAERS)
    Fahmy, Ahmed I.
    Mekkawy, Mohamed A.
    Abou-Ali, Adel
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2017, 26 : 186 - 186
  • [35] Bevacizumab and gastrointestinal perforations: a review from the FDA Adverse Event Reporting System (FAERS) database
    Wichelmann, Thomas A.
    Abdulmujeeb, Sufyan
    Ehrenpreis, Eli D.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2021, 54 (10) : 1290 - 1297
  • [36] A Real-World Pharmacovigilance Study of FDA Adverse Event Reporting System (FAERS) for Mavacamten
    Yukselen, Zeynep
    Raju, Arvind Kumar Venkataramana
    Kumar, Pramukh Arun
    Ujjawal, Aditi
    Dasari, Mahati
    Parajuli, Shreyash
    Nakhla, Michael
    Bansal, Kannu
    Ganatra, Sarju
    Dani, Sourbha S.
    AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS, 2024, 24 (06) : 791 - 799
  • [37] Post-Marketing Pharmacovigilance of Canakinumab from the FDA Adverse Event Reporting System (FAERS)
    Zhang, Weidong
    Chen, Yunzhou
    Yao, Zeyu
    Ouyang, Mengling
    Sun, Minghui
    Zou, Shupeng
    PHARMACEUTICALS, 2025, 18 (01)
  • [38] WEBER EFFECT: AN EXTENDED ANALYSIS FOR TEN YEARS OF REPORTING TRENDS IN FDA ADVERSE EVENT REPORTING SYSTEM (FAERS)
    Beulah, E.
    Reddy, N.
    Subeesh, V
    Maheswari, E.
    Pudi, C.
    VALUE IN HEALTH, 2018, 21 : S369 - S369
  • [39] Metformin adverse event profile: a pharmacovigilance study based on the FDA Adverse Event Reporting System (FAERS) from 2004 to 2022
    Du, Yikuan
    Zhu, Jinfeng
    Guo, Zhuoming
    Wang, Zhenjie
    Wang, Yuni
    Hu, Mianda
    Zhang, Lingzhi
    Yang, Yurong
    Wang, Jinjin
    Huang, Yixing
    Huang, Peiying
    Chen, Mianhai
    Chen, Bo
    Yang, Chun
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2024, 17 (02) : 189 - 201
  • [40] Atezolizumab and severe cutaneous adverse reactions: Data mining of the FDA Adverse Event Reporting System (FAERS) database
    Pecere, A.
    Bisinella, G. C.
    ANNALS OF ONCOLOGY, 2021, 32 : S1251 - S1251